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 A wearable haemodialysis device potentially holds out the promise to the dialysis 
patient freedom to carry on with their life, without dietary and fluid restrictions.  A 
recent trial reported on treating patients for 24 hours, a small but important step 
forward in the development of a wearable device.  
 
Words 1001 
3 million patients with chronic kidney disease are treated world-wide by haemodialysis. 
Although this would suggest that haemodialysis is a successful life supporting 
treatment, one only has to scratch under the surface to realise that the 5 year survival 
in economically advanced is less than that for several common solid organ malignancies 
[1]. In addition haemodialysis is an expensive treatment which limits availability to 
patients in economically developing countries.  
Haemodialysis requires a dialyzer with rapid small solute clearance through which blood 
and dialysate are pumped in counter-current directions. Sessions typically last 4 hours 
or less thrice weekly. Due to the intermittent treatment patients are requested to 
restrict dietary intake of sodium, potassium, phosphate, and fluid intake to limit weight 
gains between dialysis sessions. During the haemodialysis session fluid that has 
accumulated is removed, so the commonest complication during haemodialysis is 
hypotension. The rapid clearance of small solutes leads to changes in plasma osmolality 
and reverse water movement into the brain, so in addition to symptoms related to 
hypotension, most patients feel tired post dialysis, and this fatigue may take from 
minutes to more than a day to resolve [2]. Although some patients benefit from home 
haemodialysis, the majority dialyse in dialysis centres, often having to adapt their life 
style to fixed sessions and the time spent travelling to and from centres. Not 
surprisingly many patients are unable to continue with employment, and self-reported 
depression rates are high [3].  
Gura and colleagues now report on the use of a wearable haemodialysis device [4]. A 
wearable device would potentially allow patients to mobilise during treatment, so 
allowing them to move around and perform normal activities. In addition by working 24 
hours a day, it would allow slower removal of both fluid and uraemic toxins, so 
potentially reducing inter-dialytic symptoms and the risk of hypotension. To be 
acceptable to the patient the wearable the device has to be lightweight and 
ergonomically comfortable to wear. On the other hand the device has to operate for as 
long as possible, so that the patient does not have to regularly replace parts [5]. 
Compared to the standard haemodialysis treatment, the device uses a fixed dialysate 
volume of 375 ml, which then has to be regenerated by passing through a series of 
sorbents and ion exchangers. As these do not substantially remove urea, urea is 
enzymatically converted by urease added to the sorbents to ammonia, which is then 
converted into ammonium carbonate, leading to the generation of carbon dioxide [6]. To 
prevent bubbles of carbon dioxide disrupting flow in the dialysate circuit, a gas 
permeable section of tubing was inserted between the sorbents and the dialyzer. A 
battery operated single mini-pump powered blood and dialysate in counter-current 
directions through a standard dialyzer. Four additional pumps were required to regulate 
ultrafiltration flow, administration of heparin for anticoagulation, and one each for an 
electrolyte mixture and sodium bicarbonate solution used to refresh the dialysate. 
Seven patients were treated, connected to the wearable haemodialysis device using 
central venous access catheters. Five patients completed the 24 hour treatment. 
Ideally this device would be worn at home, and as such the first hurdle is to establish 
safety.  One patient stopped using the device due to circuit clotting, another due to 
multiple technical problems. Two patients required battery exchanges for the blood 
pump. Three patients required interventions to remove air bubbles from the blood 
circuit, thought to have come from air left within the dialyzer during initial circuit 
priming. One patient had to have the sorbent cartridges replaced. A common problem 
encountered was small bubbles of carbon dioxide which were not fully eliminated by the 
gas permeable chamber, and these would intermittently reduce dialysate flows. As 
patients were allowed to move around freely, then blood flows intermittently fell due to 
mechanical kinking of blood lines. These later problems can be overcome by redesign of 
the circuit, increasing the capacity of the gas permeable section, and using different 
plastic polymers for the blood and dialysate lines. 
In terms of clearances, as expected with the much slower blood (42±24 ml/min) and 
dialysate (43±20 ml/min) flows, the instantaneous clearances were much lower than 
during a standard conventional haemodialysis session.  However whereas the clearance 
of urea with standard intermittent haemodialysis would be substantially greater than 
that for creatinine, and creatinine much greater than for phosphate, clearances with 
the wearable device were very similar; urea 17±10 ml/min, creatinine 16±8 ml/min and 
phosphate 15±9 ml/min. Patients started treatment very shortly after completing a 
standard haemodialysis treatment, and blood urea concentrations did increase over the 
24 hour treatment period, suggesting that the amount of urease in the sorbent 
cartridges was unable to cope with urea generation rates. Blood flows appeared to 
decline after 16 hours, so clearances did fall in most patients (Figure). However the 
rise in blood urea was apparent after 8 hours, before this reduction in blood flow. On 
the other hand although β2 microglobulin clearance was lower at 5±4 ml/min, serum β2 
microglobulin levels did not rise, suggesting that β2 microglobulin removal was equal to 
the production rate [7]. This suggests a key advantage for the wearable device, as 
larger solutes, and in particular those protein bound uraemic toxins are not effectively 
cleared by conventional haemodialysis [8], whereas they would potentially be cleared by 
the wearable device. 
Patients tolerated treatment very well. They were allowed to eat and drink, and 
1002±380 ml was removed by ultrafiltration, with no significant change in blood 
pressure [9], although blood pressure appeared to be a little lower after 8 hours of 
treatment. More importantly patient feedback in terms of lack of inter-dialytic 
symptoms, zero to minimal recovery time post treatment was very positive. In addition 
patients were equally positive in their perception of the potential for this device in 
terms of allowing treatment flexibility, freedom and improved life style. Although a 
small step forward in the development of a wearable haemodialysis device, the device 
worked and the concept remains on course. Lessons were learnt for a redesigned 
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Figure. Average clearance of urea, creatinine, phosphate, β2 microglobulin and 
corresponding blood and dialysate flows. 
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